The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity
- PMID: 11694533
- DOI: 10.1074/jbc.M108525200
The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity
Abstract
The delta isoform of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) predominates in the heart. To investigate the role of CaMKII in cardiac function, we made transgenic (TG) mice that express the nuclear delta(B) isoform of CaMKII. The expressed CaMKIIdelta(B) transgene was restricted to the myocardium and highly concentrated in the nucleus. Cardiac hypertrophy was evidenced by an increased left ventricle to body weight ratio and up-regulation of embryonic and contractile protein genes including atrial natriuretic factor, beta-myosin heavy chain, and alpha-skeletal actin. Echocardiography revealed ventricular dilation and decreased cardiac function, which was also observed in hemodynamic measurements from CaMKIIdelta(B) TG mice. Surprisingly, phosphorylation of phospholamban at both Thr(17) and Ser(16) was significantly decreased in the basal state as well as upon adrenergic stimulation. This was associated with diminished sarcoplasmic reticulum Ca(2+) uptake in vitro and altered relaxation properties in vivo. The activity and expression of protein phosphatase 2A were both found to be increased in CaMKII TG mice, and immunoprecipitation studies indicated that protein phosphatase 2A directly associates with CaMKII. Our findings are the first to demonstrate that CaMKII can induce hypertrophy and dilation in vivo and indicate that compensatory increases in phosphatase activity contribute to the resultant phenotype.
Similar articles
-
CaMKII-mediated increased lusitropic responses to beta-adrenoreceptor stimulation in ANP-receptor deficient mice.Cardiovasc Res. 2007 Mar 1;73(4):678-88. doi: 10.1016/j.cardiores.2006.10.003. Epub 2006 Oct 7. Cardiovasc Res. 2007. PMID: 17107670
-
CaMKIIdelta overexpression in hypertrophy and heart failure: cellular consequences for excitation-contraction coupling.Braz J Med Biol Res. 2005 Sep;38(9):1293-302. doi: 10.1590/s0100-879x2005000900002. Epub 2005 Aug 26. Braz J Med Biol Res. 2005. PMID: 16138211 Review.
-
Cardiomyocyte calcium and calcium/calmodulin-dependent protein kinase II: friends or foes?Recent Prog Horm Res. 2004;59:141-68. doi: 10.1210/rp.59.1.141. Recent Prog Horm Res. 2004. PMID: 14749501 Review.
-
The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure.Circ Res. 2003 May 2;92(8):912-9. doi: 10.1161/01.RES.0000069686.31472.C5. Epub 2003 Apr 3. Circ Res. 2003. PMID: 12676814
-
Expression of Ca2+/calmodulin-dependent protein kinase II delta-subunit isoforms in rats with hypertensive cardiac hypertrophy.Mol Cell Biochem. 2001 Apr;220(1-2):69-76. doi: 10.1023/a:1010899724222. Mol Cell Biochem. 2001. PMID: 11451385
Cited by
-
Role of CAMK2D in neurodevelopment and associated conditions.Am J Hum Genet. 2024 Feb 1;111(2):364-382. doi: 10.1016/j.ajhg.2023.12.016. Epub 2024 Jan 24. Am J Hum Genet. 2024. PMID: 38272033
-
Calcium/calmodulin-dependent protein kinase II associates with the K+ channel isoform Kv4.3 in adult rat optic nerve.Front Neuroanat. 2022 Sep 8;16:958986. doi: 10.3389/fnana.2022.958986. eCollection 2022. Front Neuroanat. 2022. PMID: 36172564 Free PMC article.
-
CaMKII as a Therapeutic Target in Cardiovascular Disease.Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:249-272. doi: 10.1146/annurev-pharmtox-051421-111814. Epub 2022 Aug 16. Annu Rev Pharmacol Toxicol. 2023. PMID: 35973713 Free PMC article. Review.
-
Emerging therapeutic targets for cardiac hypertrophy.Expert Opin Ther Targets. 2022 Jan;26(1):29-40. doi: 10.1080/14728222.2022.2031974. Epub 2022 Jan 27. Expert Opin Ther Targets. 2022. PMID: 35076342 Free PMC article. Review.
-
Cardiac involvement in cystic fibrosis evaluated using cardiopulmonary magnetic resonance.Int J Cardiovasc Imaging. 2022 May;38(5):1121-1131. doi: 10.1007/s10554-021-02496-6. Epub 2022 Jan 7. Int J Cardiovasc Imaging. 2022. PMID: 34994881 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous